Skip to content

Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases With Epidemic Potential in Mali

Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05441800
Acronym
ECERID
Enrollment
400
Registered
2022-07-01
Start date
2020-06-18
Completion date
2023-06-18
Last updated
2022-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile Illness

Keywords

Unknown febrile, emerging or, re-emerging infectious disease

Brief summary

This is a prospective observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases.

Detailed description

Infectious diseases remain one of the leading causes of death worldwide despite innovations in medical research and the availability of new treatments. Emerging diseases include outbreaks of previously unknown diseases or known diseases where the incidence in humans has significantly increased in the past two decades. Detailed studies on emerging and re-emerging infectious agents to better understand pathogens' biology and host pathogenesis are mostly lacking. This study protocol is to prepare for a rapid coordinated clinical investigation of acute infections of emerging and re-emerging infectious agents in Mali. In collaboration with the Mali Ministry of Health and Public Hygiene, we will conduct an observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases. Patients with suspected emerging or re-emerging infectious diseases within 15 km of Point G Hospital in Bamako will be invited to participate in this study.

Interventions

OTHERObservational Study

observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
University Clinical Research Center, Mali
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Participants referred or managed by the National Disease Surveillance Committee, primary healthcare facilities, level-3 hospitals, or other facilities Adults and children of any age Unexplained fever (temperature greater than or equal to 38°C), recorded or reported, within 24 to 48 hours, regardless duration with at least one of the following signs or symptoms: * Unexplained bleeding * One or more generic symptoms (headache, tiredness, myalgia, arthralgia, diarrhea, anorexia, weight loss, rash) * Jaundice * One or more respiratory symptoms (cough, dyspnea, pharyngitis, rhinorrhea) * Guillain-Barré syndrome * Newborns with microcephaly or other brain defects * Agree to have samples collected and stored for further studies

Exclusion criteria

\- Participants may be excluded from enrolling in the study if they have any known medical disorders or other circumstances which, in the opinion of the investigator, might make participation unsafe or difficult (e.g. inability to obtain necessary samples, mental illness).

Design outcomes

Primary

MeasureTime frameDescription
Identify the etiologies and immediate outcomes of emerging and re-emerging diseases in Mali.In 3 yearsTo identify the etiologies (e.g. lassa fever, measles, covid-19, zika, Ebola virus disease) of unexplained febrile illnesses in adults and children in Mali measured by the proportion of cases identified who are children, or who are adults.

Countries

Mali

Contacts

Primary ContactSounkalo DAO, MD
sounkalod@icermali.org+223 72 27 49 71
Backup ContactOumar GUINDO, PharmD, MPH
oumarmguindo@gmail.com+22376410338

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026